You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Table TDI-21. Gender ratio by primary drug - ratio of males to females among new and all clients entering outpatient and inpatient treatment in 2005 for countries supplying data [see all tables in this series...]

Part (i) Gender ratio (ratio of males to females) among new clients entering outpatient treatment

Country		Opioids	Cocaine	Stimulants	Hypnotics and sedatives	Hallucinogens	Volatile substances	Cannabis	Other drugs	Base (known status)
Bulgaria	(1)	3.6	1.0					3.9		199
Czech Republic	(2)	2.5		1.4	1.0	0.5	3.5	3.3		1044
Denmark	(3)	2.9	3.6	2.3	0.8			3.5	3.2	1290
Germany		3.4	6.5	2.3	0.6	2.7	1.8	6.9	4.5	13933
Ireland	(4)	2.4	4.3	3.8	1.9		1.1	6.0		1530
Greece	(5)	6.3	4.0	1.0	3.5	2.0	0.3	5.0		1179
Spain	(6)	2.9	6.0	3.6	1.2	7.3	7.5	6.0	2.1	26117
France		3.2	2.7	2.8	1.0	5.5	1.0	6.2	2.4	3877
Italy	(7)	4.9	10.3	4.2	1.0			10.2	1.4	34801
Cyprus	(8)	5.9	4.6		1.0	29.0		6.5		214
Latvia	(9)	3.2	1.0	2.8	1.7		18.0	7.5	1.9	399
Lithuania	(10)	3.7		4.7	0.3				5.0	369
Hungary		2.9	2.7	3.7	0.5	3.6	10.0	8.3	1.3	4597
Malta	(11)	4.8	4.8	4.0				5.3		299
Netherlands	(12)	3.9	4.6	2.6	0.9	8.0	2.0	4.1	0.5	4299
Portugal		6.6	6.1		1.3			8.4	4.2	2876
Slovakia	(13)	2.4		2.5	0.3		7.0	6.8		456
Finland	(14)	1.7	0.5	1.2	1.5			2.7		407
Sweden		0.8	9.3	1.1	0.7	3.0	1.0	3.2	3.4	765
United Kingdom		2.6	3.1	1.6	1.0	2.5	1.5	3.3	2.1	37519
Total		3.4	5.8	2.0	0.9	3.8	2.3	6	2.0	4.1
Total base		51119	32097	6675	2836	267	419	40712	2044	136170

Notes:

(1) No female cases for stimulants, hypnotics and other drugs; no cases for hallucinogens and volatile substances.

(2) No female cases for cocaine; no cases for other drugs.

(3) No male cases for Volatile substances; no female cases for hallucinogens.

(4) No male cases for other drugs; no female cases for hallucinogens.

(5) No female cases for other drugs.

(6) Data refer to 2004.

(7) No female cases for hallucinogens and volatile substances.

(8) No female cases for; no cases for Volatile substances and other drugs.

(9) No female cases hallucinogens.

(10) No male cases for cannabis; no female cases for hallucinogens, volatile substances and cocaine.

(11) No female cases for hypnotics, hallucinogens and volatile substances; no cases for other drugs.

(12) No female cases for stimulants and volatile substances; no cases for hallucinogens.

(13) No female cases for cocaine, hallucinogens and other drugs.

(14) No male cases for other drugs; no female cases for Volatile substances and no cases for hallucinogens.

See also 'General notes for interpreting data' on the Explanatory notes and help page.

Sources:

2006 Reitox national reports - TDI - outpatient treatment centres.